The update was requested by the FDA based on data supporting the significant LDL-C lowering abilities of PCSK-targeting therapies.

The updated label no longer requires Leqvio (inclisiran) to be used in combination with statins for low-density lipoprotein ...

Novartis announced the FDA approved updated labeling for inclisiran, a small-interfering RNA therapy, for use as monotherapy ...

Note that some links may require registration or subscription. Justin Timberlake said he has been diagnosed with Lyme disease ...

Shares of European pharmaceutical companies sold off on Friday after President Donald Trump sent letters to 17 companies, including U.S. firms, in the sector.

Novartis announced today that the US Food and Drug Administration (FDA) has approved a label update for Leqvio® (inclisiran), enabling its use as monotherapy along with diet and exercise to reduce low ...

Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.

Novartis reported an impressive 11% increase in sales in constant currency, accompanied by a 21% rise in core operating income for Q2 2025. This growth underscores the company’s strong financial ...

Q2 2025 Earnings Call Transcript July 21, 2025 Operator: Good morning and good afternoon, and welcome to the Novartis Q2 2025 ...

The company has a plethora of growth drivers in its commercial portfolio, including neurology drug Kesimpta, cardiovascular drug Leqvio, cancer drugs Kisqali, Pluvicto, and Scemblix, and rare ...

Novartis AG (NVS) reports robust sales and income growth, announces a $10 billion share buyback, and navigates competitive challenges.

Other strong performers included Leqvio, up 61% globally, and Scemblix, which surged 79% in constant currency. Entresto, one of Novartis’ top-selling drugs, generated $1.2 billion in Q2 sales, though ...